GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » EV-to-FCF

Prime Medicine (Prime Medicine) EV-to-FCF : -3.25 (As of May. 11, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Prime Medicine's Enterprise Value is $565.33 Mil. Prime Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-174.14 Mil. Therefore, Prime Medicine's EV-to-FCF for today is -3.25.

The historical rank and industry rank for Prime Medicine's EV-to-FCF or its related term are showing as below:

PRME' s EV-to-FCF Range Over the Past 10 Years
Min: -8.93   Med: 0   Max: 0
Current: -3.25

PRME's EV-to-FCF is ranked worse than
100% of 390 companies
in the Biotechnology industry
Industry Median: 6.365 vs PRME: -3.25

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Prime Medicine's stock price is $5.61. Prime Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.180. Therefore, Prime Medicine's PE Ratio for today is At Loss.


Prime Medicine EV-to-FCF Historical Data

The historical data trend for Prime Medicine's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine EV-to-FCF Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -10.42 -4.33

Prime Medicine Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.42 -7.00 -7.93 -4.76 -4.33

Competitive Comparison of Prime Medicine's EV-to-FCF

For the Biotechnology subindustry, Prime Medicine's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prime Medicine's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Prime Medicine's EV-to-FCF falls into.



Prime Medicine EV-to-FCF Calculation

Prime Medicine's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=565.330/-174.136
=-3.25

Prime Medicine's current Enterprise Value is $565.33 Mil.
Prime Medicine's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-174.14 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prime Medicine  (NAS:PRME) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Prime Medicine's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.61/-2.180
=At Loss

Prime Medicine's share price for today is $5.61.
Prime Medicine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.180.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Prime Medicine EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Prime Medicine's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Prime Medicine (Prime Medicine) Business Description

Traded in Other Exchanges
N/A
Address
21 Erie Street, Cambridge, MA, USA, 02139
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Executives
Gv 2019 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Alphabet Inc. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Robert Nelsen director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Thomas Cahill director PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Arch Venture Partners X, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson officer: See Remarks 88 SIDNEY STREET, CAMBRIDGE MA 02139
Keith Crandell 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Kaye I Foster-cheek director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Meredith Goldwasser officer: SVP, Strategy & Corporate Ops. PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139